Cargando…

Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial

OBJECTIVE: To evaluate whether probiotic supplementation attenuates gut-dysbiosis in neonates with congenital gastrointestinal surgical conditions (CGISC). METHODS: Sixty-one neonates (≥35 weeks gestation) with CGISC were randomised to receive daily supplementation with a triple-strain bifidobacteri...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Shripada, Esvaran, Meera, Chen, Liwei, Keil, Anthony D., Gollow, Ian, Simmer, Karen, Wemheuer, Bernd, Conway, Patricia, Patole, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722408/
https://www.ncbi.nlm.nih.gov/pubmed/34980887
http://dx.doi.org/10.1038/s41390-021-01884-x
_version_ 1784625519613968384
author Rao, Shripada
Esvaran, Meera
Chen, Liwei
Keil, Anthony D.
Gollow, Ian
Simmer, Karen
Wemheuer, Bernd
Conway, Patricia
Patole, Sanjay
author_facet Rao, Shripada
Esvaran, Meera
Chen, Liwei
Keil, Anthony D.
Gollow, Ian
Simmer, Karen
Wemheuer, Bernd
Conway, Patricia
Patole, Sanjay
author_sort Rao, Shripada
collection PubMed
description OBJECTIVE: To evaluate whether probiotic supplementation attenuates gut-dysbiosis in neonates with congenital gastrointestinal surgical conditions (CGISC). METHODS: Sixty-one neonates (≥35 weeks gestation) with CGISC were randomised to receive daily supplementation with a triple-strain bifidobacterial probiotic (n = 30) or placebo (n = 31) until discharge. Stool microbiota was analysed using 16S ribosomal RNA gene sequencing on samples collected before (T1), 1 week (T2), and 2 weeks (T3) after supplementation and before discharge (T4). The primary outcome was the sum of the relative abundance of potentially pathogenic families of Clostridiaceae, Enterobacteriaceae, Enterococcaceae, Pseudomonaceae, Staphylococcaeae, Streptococcaceae, and Yersiniaceae at T3. RESULTS: The median gestational age [38 weeks (IQR: 37.1–38.9)] was similar in both groups. The probiotic group had lower rates of caesarean deliveries (40% versus 70%, p = 0.02). The relative abundance of potentially pathogenic families was lower in the probiotic group compared to placebo at T3 [(median: 50.4 (IQR: 26.6–67.6) versus 67.1 (IQR: 50.9–96.2); p = 0.04). Relative abundance of Bifidobacteriaceae was higher in the probiotic group at T3 [(median: 39.8 (IQR: 24.9–52.1) versus 0.03 (IQR 0.02–2.1); p < 0.001). Stratified analysis continued to show a higher abundance of Bifidobacteriaceae in the probiotic group, irrespective of the mode of delivery. CONCLUSIONS: Probiotic supplementation attenuated gut dysbiosis in neonates with CGISC. TRIAL REGISTRATION: http://www.anzctr.org.au (ACTRN12617001401347). IMPACT: Probiotic supplementation attenuates gut dysbiosis and improves stool short-chain fatty acid levels in neonates with congenital gastrointestinal surgical conditions. This is the second pilot RCT of probiotic supplementation in neonates with congenital gastrointestinal conditions. These findings will pave the way for conducting multicentre RCTs in this area.
format Online
Article
Text
id pubmed-8722408
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-87224082022-01-04 Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial Rao, Shripada Esvaran, Meera Chen, Liwei Keil, Anthony D. Gollow, Ian Simmer, Karen Wemheuer, Bernd Conway, Patricia Patole, Sanjay Pediatr Res Clinical Research Article OBJECTIVE: To evaluate whether probiotic supplementation attenuates gut-dysbiosis in neonates with congenital gastrointestinal surgical conditions (CGISC). METHODS: Sixty-one neonates (≥35 weeks gestation) with CGISC were randomised to receive daily supplementation with a triple-strain bifidobacterial probiotic (n = 30) or placebo (n = 31) until discharge. Stool microbiota was analysed using 16S ribosomal RNA gene sequencing on samples collected before (T1), 1 week (T2), and 2 weeks (T3) after supplementation and before discharge (T4). The primary outcome was the sum of the relative abundance of potentially pathogenic families of Clostridiaceae, Enterobacteriaceae, Enterococcaceae, Pseudomonaceae, Staphylococcaeae, Streptococcaceae, and Yersiniaceae at T3. RESULTS: The median gestational age [38 weeks (IQR: 37.1–38.9)] was similar in both groups. The probiotic group had lower rates of caesarean deliveries (40% versus 70%, p = 0.02). The relative abundance of potentially pathogenic families was lower in the probiotic group compared to placebo at T3 [(median: 50.4 (IQR: 26.6–67.6) versus 67.1 (IQR: 50.9–96.2); p = 0.04). Relative abundance of Bifidobacteriaceae was higher in the probiotic group at T3 [(median: 39.8 (IQR: 24.9–52.1) versus 0.03 (IQR 0.02–2.1); p < 0.001). Stratified analysis continued to show a higher abundance of Bifidobacteriaceae in the probiotic group, irrespective of the mode of delivery. CONCLUSIONS: Probiotic supplementation attenuated gut dysbiosis in neonates with CGISC. TRIAL REGISTRATION: http://www.anzctr.org.au (ACTRN12617001401347). IMPACT: Probiotic supplementation attenuates gut dysbiosis and improves stool short-chain fatty acid levels in neonates with congenital gastrointestinal surgical conditions. This is the second pilot RCT of probiotic supplementation in neonates with congenital gastrointestinal conditions. These findings will pave the way for conducting multicentre RCTs in this area. Nature Publishing Group US 2022-01-03 2022 /pmc/articles/PMC8722408/ /pubmed/34980887 http://dx.doi.org/10.1038/s41390-021-01884-x Text en © Crown 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Clinical Research Article
Rao, Shripada
Esvaran, Meera
Chen, Liwei
Keil, Anthony D.
Gollow, Ian
Simmer, Karen
Wemheuer, Bernd
Conway, Patricia
Patole, Sanjay
Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial
title Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial
title_full Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial
title_fullStr Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial
title_full_unstemmed Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial
title_short Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial
title_sort probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial
topic Clinical Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722408/
https://www.ncbi.nlm.nih.gov/pubmed/34980887
http://dx.doi.org/10.1038/s41390-021-01884-x
work_keys_str_mv AT raoshripada probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial
AT esvaranmeera probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial
AT chenliwei probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial
AT keilanthonyd probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial
AT gollowian probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial
AT simmerkaren probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial
AT wemheuerbernd probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial
AT conwaypatricia probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial
AT patolesanjay probioticsupplementationinneonateswithcongenitalgastrointestinalsurgicalconditionsapilotrandomisedcontrolledtrial